Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative
Yoshinori Arai1, Seiji Arihiro, Tomokazu Matsuura
1*Division of Gastroenterology and Hepatology, Department of Internal Medicine, Departments of †Laboratory Medicine, and ‡Endoscopy, The Jikei University School of Medicine, Tokyo, Japan; §Division of Cancer Genomics, Cancer Institute of JFCR and Bioinformatics Group, Genome Center of JFCR, Japanese Foundation for Cancer Research, Tokyo, Japan; ‖Department of Clinical Pathology, Japanese Red Cross Medical Center, Tokyo, Japan; ¶Department of Pathology, Kitasato University School of Medicine, Kanagawa, Japan; and **Department of Scientific Information, Fujirebio, Inc, Tokyo, Japan. Ito is now with the IDAC Theranostics, Inc., University of Tokyo Entrepreneur Plaza, Tokyo, Japan.
Background:
C-reactive protein (CRP) is used as a biomarker of ulcerative colitis (UC) activity, but CRP levels are sometimes insufficient to reflect UC activity. Therefore, a simple noninvasive biomarker assay with sufficient sensitivity and specificity to accurately reflect UC activity is desired. Since prostaglandin E2 production and colonic inflammation are associated, we evaluated whether prostaglandin E-major urinary metabolite (PGE-MUM) can be used as such a biomarker.
Methods:
Patients with UC (n = 99) were enrolled from March 2011 to February 2012. UC activity was evaluated using the simple clinical colitis activity index in 99 patients, Mayo endoscopic scoring (Mayo) in 79 patients, and Matts' grading (Matts) in 64 patients. PGE-MUM levels were measured by radioimmunoassay kit and compared against CRP levels as a control.
Results:
Both PGE-MUM and CRP levels correlated with UC activity (P < 0.01). Areas under the receiver operating characteristic curves of simple clinical colitis activity index, Mayo, and Matts for PEG-MUM were each higher than for CRP (0.93 > 0.73, 0.90 > 0.77, and 0.89 > 0.75, respectively). In multivariate logistic regression models, PGE-MUM was a significant independent predictor of histologic remission (sensitivity/specificity, 0.82/0.82) when the cutoff value was set to 17.0 μg/g creatinine, but CRP was not (0.69/0.69) (P < 0.01).
Conclusions:
Compared with CRP level, PGE-MUM level demonstrated better sensitivity for reflecting UC activity, especially in cases of histologic inflammation, and thus seems to be a better evaluator of mucosal healing. Because this method is simple, quick, and noninvasive, PGE-MUM seems to be a useful biomarker of UC.
More Related Videos
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:29Drugs for Treatment of Ulcerative Colitis in IBD